Clinical Trial Site

Cardiff CF5 4AD

5 studies enrolling now · 11 studies all time

What they study most

ANCA-Associated Vasculitis, Acute Hepatic Porphyria, Atypical Hemolytic Uremic Syndrome (aHUS), Atypical Hemolytic-Uremic Syndrome, Familial Amyloidotic Cardiomyopathy (FAC), High Cardiovascular Risk, High Risk Cardiovascular Disease, Hypertension, Transthyretin Amyloidosis (ATTR) With Cardiomyopathy, Transthyretin Amyloidosis With Cardiomyopathy

Studies at this site

• TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy — Recruiting now
• Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease — Recruiting now
• ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP) — Recruiting now
• Atypical Hemolytic-Uremic Syndrome (aHUS) Registry — Recruiting now
• APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy) — Completed
• Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) — Completed
• A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy — Enrolling by invitation
• HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy — Running, not enrolling
• A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis — Completed
• Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) — Completed
• DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis — Completed